Full Text
Additional Benefit Scoring During Health Technology Assessment in Germany - Its Drivers and Impact on Pricing and Discount for Orphan Drugs

Abstract

Authors

Y Oku A Fukushima J Dorey M Toumi

Back to Volume 21, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×